Metronidazol Fresenius

Metronidazole, the active ingredient in Metronidazol Fresenius, is a nitroimidazole antibiotic presented as an injection for intravenous use. It treats anaerobic bacterial infections and certain protozoal diseases in adults and children as prescribed, and is indicated for a range of infections caused by susceptible anaerobic bacteria and protozoa.

GNH USA supplies Metronidazol Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality‑assured products and reliable logistics across regulated markets throughout the globe.

Metronidazole is used to treat infections caused by anaerobic bacteria and certain protozoa.

- Bacterial vaginosis: restores normal vaginal flora by eliminating anaerobic bacteria. - Trichomoniasis: eradicates Trichomonas vaginalis, relieving symptoms and preventing transmission. - Amoebiasis: clears intestinal Entamoeba histolytica infection, reducing dysentery and liver abscess risk. - Anaerobic bacterial infections: controls intra‑abdominal, pelvic, skin and soft‑tissue infections caused by susceptible anaerobes. - Clostridioides difficile infection: reduces toxin‑producing C. difficile overgrowth in selected cases.

Metronidazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset. - Metallic taste: transient metallic sensation. - Headache: mild headache. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Seizures: convulsions, especially with high doses. - Peripheral neuropathy: tingling or numbness in extremities. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Anaphylaxis: acute allergic reaction with respiratory distress.

Metronidazol Fresenius should be used with careful clinical assessment and monitoring. - Renal impairment: adjust dose or monitor plasma levels in patients with reduced kidney function. - Hepatic disease: use with caution in liver dysfunction, monitor liver enzymes. - Alcohol consumption: avoid alcohol during and for at least 48 hours after therapy to prevent disulfiram‑like reaction. - Pregnancy: category B; generally considered safe but use only if benefits outweigh risks. - Concomitant CNS depressants: monitor for enhanced central nervous system effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metronidazol Fresenius can interact with several medicines; clinicians should review patient medication lists.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, tachycardia, nausea, and vomiting. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: may increase lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Cimetidine: can raise metronidazole plasma concentrations. - Phenytoin: may reduce metronidazole efficacy. - Rifampicin: may decrease metronidazole levels.